Loading...
  • InDex Pharmaceuticals logo SVE
  • InDex Pharmaceuticals logo ENG
InDex Pharmaceuticals logo
  • About Us
    About Us
    Close
    • InDex Pharmaceuticals in brief
      CEO corner
      Business model
    • Corporate governance
      General meetings
      Nomination committee
      Board of directors
      Work of the board of directors
      Management
      Remuneration and incentive programmes
      Auditors
      Articles of association
    • Advisory Board North America
      Advisory Board Europe
  • Research & Development
    Research & Development
    Close
    • Technology platform & pipeline
      Scientific articles
    • Cobitolimod
      About ulcerative colitis and today's standard of care
      A new opportunity with cobitolimod
      Clinical studies
      Phase III program CONCLUDE
      Questions and answers on CONCLUDE
    • CONDUCT
      The CONDUCT study
      Study design
      Frequently asked questions about CONDUCT
  • Ulcerative Colitis
    Ulcerative Colitis
    Close
    • About ulcerative colitis and today's standard of care
      Living with ulcerative colitis - read patient stories
    • About cobitolimod
      Phase III program CONCLUDE
    • About clinical trials
      Additional information
  • Investors
    Investors
    Close
    • Invest in InDex Pharmaceuticals
      The share
      Dividend and dividend policy
      Shareholders
      InDex Pharmaceuticals on Nasdaq First North Growth Market
    • Financial reports
      Presentations
      Press releases
      Subscribe
      Financial calendar
    • Analysts
      Prospectus archive
      Certified Adviser
      IR contact
  • Media
    Media
    Close
    • Press releases
    • Image bank
    • Subscribe
      Media contact
  • Career
    Career
    Close
    • Career
    • Job openings
    • Open application
  • Contact
    Contact
    Close
    • IR contact
      Media contact
    • Certified Adviser
  • About Us
    • InDex Pharmaceuticals in brief
    • CEO corner
    • Business model
    • Corporate governance
      • General meetings
      • Nomination committee
      • Board of directors
      • Work of the board of directors
      • Management
      • Remuneration and incentive programmes
      • Auditors
      • Articles of association
      • Advisory Board North America
      • Advisory Board Europe
  • Research & Development
    • Technology platform & pipeline
      • Scientific articles
    • Cobitolimod
      • About ulcerative colitis and today’s standard of care
      • A new opportunity with cobitolimod
      • Clinical studies
    • Phase III program CONCLUDE
      • Questions and answers on CONCLUDE
    • CONDUCT
      • The CONDUCT study
      • Study design
      • Frequently asked questions about CONDUCT
  • Ulcerative Colitis
    • About ulcerative colitis and today’s standard of care
    • Living with ulcerative colitis – read patient stories
    • About cobitolimod
    • Phase III program CONCLUDE
    • About clinical trials
    • Additional information
  • Investors
    • Invest in InDex Pharmaceuticals
    • The share
      • Dividend and dividend policy
      • Shareholders
      • InDex Pharmaceuticals on Nasdaq First North Growth Market
    • Financial reports
    • Presentations
    • Press releases
    • Subscribe
    • Financial calendar
    • Analysts
    • Prospectus archive
    • Certified Adviser
    • IR contact
  • Media
    • Press releases
    • Image bank
    • Subscribe
    • Media contact
  • Contact
    • IR contact
    • Media contact
    • Certified Adviser

Ulcerative Colitis

We are developing cobitolimod to help patients with ulcerative colitis live a more normal life

Ulcerative colitis (UC) is a serious and chronic inflammatory bowel disease that has no cure. Approximately 0.2 percent of the world’s population suffers from UC and the number of persons living with the disease (the prevalence) is expected to increase by 0.8 percent every year. The risk of getting inflammatory bowel diseases has increased by more than ten times over the past 75 years.

In this section you can:

  • Learn more about InDex Pharmaceuticals’ drug candidate cobitolimod and the ongoing  phase III clinical study CONCLUDE
  • Read patient stories
  • Find out more information about ulcerative colitis

Please use the left-hand menu to find out more.

  • Ulcerative Colitis
    • About ulcerative colitis and today’s standard of care
    • Living with ulcerative colitis – read patient stories
    • About cobitolimod
    • Phase III program CONCLUDE
    • About clinical trials
    • Additional information

The Share

Follow the share

InDex Pharmaceuticals Holding AB
Registration number: SE 559067-6820
Phone: +46 (0)8 122 038 50 | Berzelius väg 13, 171 65 Solna, Sweden

Contact us

Subscribe

Read more about our protection of your personal data.
  • Cookies
  • Privacy Policy
  • Trademarks